

## 725 15<sup>TH</sup> STREET, NW ♦ SUITE 700 ♦ WASHINGTON, DC 20005

202-393-5725 ♦ 1-888-USBLOOD ♦ FAX: 202-393-1282

## OUR MEMBERS SERVE COMMUNITIES NATIONWIDE

Telephone Extension 36 E-mail: cbianco@americasblood.org

March 6, 2001

Linda Smallwood, PhD., Executive Secretary Blood Products Advisory Committee Office of Blood Research & Review Center for Biologics Evaluation and Research, FDA 1401 Rockville Pike, HFM-302 Rockville, MD 20852-1448

Dear Dr. Smallwood:

On behalf of America's Blood Centers, I would like to address the Blood Products Advisory Committee on March 15<sup>th</sup>. I plan to speak for approximately 5 minutes on each of the following three topics:

- The comparative sensitivity of hepatitis B Virus nucleic acid testing versus hepatitis B Surface Antigen testing;
- The implementation of nucleic acid testing for HIV and HCV; and
- Blood bags for diversion of the initial collection.

Copies of ABC's statements accompany this letter.

I waive confidentiality of the data contained in these presentation materials and grant FDA the authority to release these presentation materials to the public through electronic and/or other means deemed appropriate.

Yours Truly,

Celso Bianco, M.D.

**Executive Vice President**